939 related articles for article (PubMed ID: 26909474)
21. Personalization of prostate cancer therapy through phosphoproteomics.
Yang W; Freeman MR; Kyprianou N
Nat Rev Urol; 2018 Aug; 15(8):483-497. PubMed ID: 29752463
[TBL] [Abstract][Full Text] [Related]
22. Androgen receptor co-regulatory networks in castration-resistant prostate cancer.
Sung YY; Cheung E
Endocr Relat Cancer; 2014 Feb; 21(1):R1-R11. PubMed ID: 24152433
[TBL] [Abstract][Full Text] [Related]
23. Olaparib Targets Some Advanced Prostate Cancers.
Cancer Discov; 2016 Jan; 6(1):OF1. PubMed ID: 26658963
[TBL] [Abstract][Full Text] [Related]
24. Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies.
Kim W; Ryan CJ
Cancer; 2015 Feb; 121(3):361-71. PubMed ID: 25236176
[TBL] [Abstract][Full Text] [Related]
25. Recent Advances in DNA Repair Pathway and Its Application in Personalized Care of Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Xu C; Mao S; Jiang H
Methods Mol Biol; 2020; 2204():75-89. PubMed ID: 32710316
[TBL] [Abstract][Full Text] [Related]
26. Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting.
Miyahira AK; Cheng HH; Abida W; Ellis L; Harshman LC; Spratt DE; Simons JW; Pienta KJ; Soule HR
Prostate; 2017 Nov; 77(15):1478-1488. PubMed ID: 28925066
[TBL] [Abstract][Full Text] [Related]
27. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
Coyne GO; Takebe N; Chen AP
Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823
[TBL] [Abstract][Full Text] [Related]
28. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
29. Clinical implications of genetic aberrations in metastatic prostate cancer.
Reichert ZR; McKay RR
Curr Opin Urol; 2019 Jul; 29(4):319-325. PubMed ID: 31158106
[TBL] [Abstract][Full Text] [Related]
30. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
31. Genomics-Enabled Precision Medicine for Cancer.
Roos A; Byron SA
Cancer Treat Res; 2019; 178():137-169. PubMed ID: 31209844
[TBL] [Abstract][Full Text] [Related]
32. Cell-free and circulating tumor cell-based biomarkers in men with metastatic prostate cancer: Tools for real-time precision medicine?
Miyamoto DT; Lee RJ
Urol Oncol; 2016 Nov; 34(11):490-501. PubMed ID: 27771279
[TBL] [Abstract][Full Text] [Related]
33. Targeting the androgen receptor in metastatic castration-resistant prostate cancer.
Aragon-Ching JB
Future Oncol; 2014 Feb; 10(3):329-32. PubMed ID: 24559439
[No Abstract] [Full Text] [Related]
34. Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine.
Tsimberidou AM
Curr Probl Cancer; 2017; 41(3):176-181. PubMed ID: 28410846
[TBL] [Abstract][Full Text] [Related]
35. [Molecular diagnostics and molecular tumor board in uro-oncology : Precision medicine using the example of metastatic castration-resistant prostate cancer].
Kornienko K; Tahbaz R; Plage H; Schlomm T
Urologe A; 2022 Mar; 61(3):311-322. PubMed ID: 35157098
[TBL] [Abstract][Full Text] [Related]
36. Strategies for targeting the androgen receptor axis in prostate cancer.
Carver BS
Drug Discov Today; 2014 Sep; 19(9):1493-7. PubMed ID: 25107669
[TBL] [Abstract][Full Text] [Related]
37. [Molecular biology of castration-resistant prostate cancer].
Doucet L; Terrisse S; Gauthier H; Pouessel D; Le Maignan C; Teixeira L; Culine S
Bull Cancer; 2015 Jun; 102(6):497-500. PubMed ID: 26028493
[TBL] [Abstract][Full Text] [Related]
38. Drug discovery in advanced prostate cancer: translating biology into therapy.
Yap TA; Smith AD; Ferraldeschi R; Al-Lazikani B; Workman P; de Bono JS
Nat Rev Drug Discov; 2016 Oct; 15(10):699-718. PubMed ID: 27444228
[TBL] [Abstract][Full Text] [Related]
39. Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies.
Friedlander TW; Pritchard CC; Beltran H
Am Soc Clin Oncol Educ Book; 2017; 37():358-369. PubMed ID: 28561699
[TBL] [Abstract][Full Text] [Related]
40. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]